<strong>A New Type of Anti-dementia Drug: The Chemistry, Biological Activities and Mechanism of Action of (-) Clausenamide</strong>

Abstract

Abstract:Seven novel amides were isolated from clausena lansium (Lour) skeels, one of which is clausenamide. Clausenamide contains 4 chiral centers, which correspond to 16 enantiomers. After the identification of the configuration of 16 enantiomers, all were successfully synthesized, and the asymmetric synthesis of (+) and (-) clausenamide were completed. During this process, the production scale has been substantially increased that should be adequate to meet the clinical use. Pharmacological studies have shown that (-) clausenamide is the effective enantiomer, while (+) clausenamide is ineffective and more toxic than (-)clausenamide using different animal models. (-)clausenamide can increase cognitive function and inhibit Aβ pathology. The anti-dementia mechanism is characterized as increasing synaptic function and structural plasticity. . Together, (-)clausenamide may be a promising pharmacotherapy for the treatment of AD and other neurodegenerative disorders.

Key words:(-) clausenamide,enantiomers,cognition,Alzheimer&,rsquo,s disease (AD),synaptic plasticity

CLC Number:

R965

CHU Shi-feng, ZHANG Jun-tian.A New Type of Anti-dementia Drug: The Chemistry, Biological Activities and Mechanism of Action of (-) Clausenamide[J]. Acta Neuropharmacologica, 2014, 4(6): 33-43.

References

[1]黄量，张均田，吴克美，等光活（-）黄皮酰胺制备方法。中国发明专利。专利号：2100124630.5.

[2]Dan Fei Huang, Han Sen Lin, Liang Huang. Total systhesis of neoclausenamide and its epimer[J]. Chinese Chemical Letter, 1994, 5(5):371-372.

[3]Guo Bin Huang, Ke Mei Wu, Liang Huang, et al. Intracelluar induction of asymmetric Danzen’s condensation of aldehydes with chiral chloroaletates[J]. Chinese Chemical Letter, 1999, 10(6):441-442.

[4]黄国宾，吴克美，黄量. (+)-1S,2R,5S-8-β-萘基薄荷醇的合成[J].高等学校化学学报, 1990, 20（9）：1394-1399.

[5]Jun-tian Zhang, Liang Huang, Kemei Wu et al. Optically active clausenamides possess of the preparation thereof, pharmaceutical composition containing the same and their medical use[J]. Patent No. US:6787,564, B2. Date of Patent: Sep 7, 2004.

[6]Xing Zhou Li, Ke Mei Wu, Liang Huang. Study on the synthesis of metabolite of clausenamide(CM1)[J]. Chinese Chemical Letter, 2002, 13(6):528-530.

[7]Xin Zhou, Ke Mei Wu, Liang Huang. Study on the synthesis od metabolite CM2 of clausenamide[J]. Chemical Letter, 2003, 14(4):338-340.

[8]黄量, 王慕邹, 张均田, 手性黄皮酰胺的化学与生物学[M]//黄量, 戴立信, 手性药物的化学与生物学.北: 化学工业出版社, 2002: 6-16.

[9]Shao Lin Liu, Jun Tian Zhang. Effects of naloxone on L-clausenamide induced long term potentiation in dentate gyrus of anaesthetized rats[J]. Acta Pharmacol Sin, 1999, 20(2):112-116.

[10]Lin Xu, Shao Lin Liu, Juntian Zhang. (-)clausenamide potentiate synaptic transmission in the dentate gyrus of rats[J].Chirality, 2005, 17(5):239-244.

[11]Kang Tang, Jun Tian Zhang. Mechanism of (-)clausenamide induced calcium transient in primary culture of rat cortical neurons[J]. Life Science, 2004, 74:1427-1434.

[12]Wen Zhen Duan, Jun Tian Zhang. Stimulation of central cholinergic neurons by (-)clausenamide in vitro[J]. Acta Pharmacol Sin, 1998, 19(4):332-336.

[13]Wen Zhen Duan, Jun Tian Zhang. Effect of clausenamide on anisodine induced acrtycholine decrease and memory deficit in the mouse brain[J]. Chinese Medical Journal, 1998, 111(11):1035-1038.

[14]Xue Ying Jiang, Jun Tian Zhang. Study on the noontropic mechanism of (-)clausenamide on the formation of synapses in mouse brain[J]. J Asian Natural Products Res, 1998, 1:53-58.

[15]Dennis J Selkoe. Alzheimer’s disease is synaptic failure[J]. Science. 2000,298(5594):789-791.

[16]Na Ning, Jin Feng Hu, Jian Dong Sun et al. (-)clausenamide facilitates synaptic transmission at hippocampal schaffer collateral-CA1 synapses[J]. European J Pharmacology, 2012, 682:50-55.

[18]Jin Feng Hu, Na Ning, Wen Zhen Duan, et al. Activation of ERK1/2-CREB pathway during potentiating synaptic transmission of (-)clausenamide in rat dentate gyrus[J]. J Asian Natural Products Research, 2012, 14(3):256-262.

[19]王润生,张均田. Baxα高表达PC12细胞系的建立及（-）黄皮酰胺抗细胞凋亡作用机制的研究[J].药学学报，2000, 35（6）：404-407.

[20]张均田,王润生, 段文贞. 光活黄皮酰胺的抗神经细胞凋亡作用及作用机制的研究[m].//中国医学科学院中国协和医科大学科研处编.科学年会论文集.北京：中国协和医科大学出版社，2000:187-192.

[21]张静, 程勇, 张均田. 左旋黄皮酰胺对冈田酸和β淀粉样肽25-35神经毒性的保护作用[J]. 药学学报, 2007,42(9): 935-942.

[22]张均田.黄皮叶中具有促智作用的黄皮酰胺类化合物的化学和生物学研究[M]//中草药现代研究.北京.中国协和医科大学出版社, 2010:355-360.

[23]Hutt A J, Tan S C. Drugs chirality and its significance[J]. Drug, 1966, 52(suppl 5):1-12.

[24]Crossley R. The relevance of chirality to the study of biological activity[J]. Tetrahedron, 1992, 48(38):8155-8178.

[25]Tokuma Y, Neguchi H. stereoselective pharmacokinetics of dihydropyridine calcium antagonists[J]. J chrom A, 1995, 694:181-193.

[26]Caldwell J. Importance of stereospecific bioanalytical monitoring in drug development[J]. J chrom A, 1996, 719: 3-13.

[27]Williams K M Chirality: pharmacokinetics and pharmacodynamics in 3 dimensions[J]. Chiral and Exper Pharmacol Physio, 1989, 16:465-470.

[28]戴立信. 绪论[M]//见黄量戴立信,手性药物的化学与生物学.北京化学工业出版社 2002:1-6.

[29] A J Bayer, R Bullock, R W Jones, et al. Evaluation of the safety and immunogenicity of synthetic Aβ42 in patient with AD[J].Neurology, 2005, 64(1):94-101.

[30]徐庆中，卢德宏，董彬，等．Alzheimer’型老年痴呆的神经病理学[M]// 盛树力．老年性痴呆从分子生物学到临床诊治.北京：科学文献出版社，1998:78-79

[31] Dennis J Selkoe．Alzheimer’s disease in a synaptic failure[J]. Science, 2000, 298(5594)：789-791.

[32] Robert D．Terry Some morphometric aspects of the brain in senile dementia of the Alzheimer type[J]. Ann Neuro1, 1981, 10(2): 184-l92.

[33]Veronica A Alvanez, Bernando L Sabatini. Anatomical and physiological plasticity of dendritic spines[J]. Annu Rev Neurosci, 2007, 30:79-97.

[34]Claudia Ferez-Cruz. Reduced spine density in specific regions of CA 1 pyramidal neurons in two transgenic mouse models of Alzheimer’s disease [J].J Neurosci, 2011, 31(10)：3926-3934.

[35] Ryan Clare, Victoria G King, Martin Wirenfeldt, et a1.Vinters．Synapse loss in dementias[J].J Neurosci Res, 2010, 88 (101):2083-2090.

[36]Veronica A Alvarez, Bernardo L Sabatini, Annu Rev. Anatomieal and physiological plasticity of dendritic spines[J]. Annu Rev Neurosci, 2007, 30:79-97.

[37]Giles E, Hardinham, Hilmar Bading. Synaptic versus extra-synaptic NMDA receptor signaling：implications for neuro-degenerative disorders[J].Nat Rev Neurosci, 2010, 10:682-696.

[38]张均田，郑永芳．细胞内钙和钙通道[M]//韩济生．神经科学原理．上册2版，北京：北京医科大学出版社，1999：222-240.

[39]Kelly AFoster, Nathan McLaughlin, Dieter Edbauer, et a1．Distinct roles of NR2A and NR2B cytoplasmic tails in long term potentiation [J]. J Neurosci, 20l0, 30(7)：2676-2685

[40] Boeckers TM. The postsynaptic density[J]. Cell Tissue Res, 2006, 326(2)：409-422.

[41]Gong Yuesong, Card F Lippa. Disruption of the postsynaptic density in Alzheimer’s disease and other neurOdegenerative dementias[J]. Am J Alzheimers Dis Other Demen, 2010, 25(71)：547-555.

A New Type of Anti-dementia Drug: The Chemistry, Biological Activities and Mechanism of Action of (-) Clausenamide

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

[1]	YANG-Lin，AI-Jing.Research Progress of Brain-Derived Estrogen in Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2019, 9(5): 50-64.
[2]	ZHANG Shuai，AI Jing.Glutamate Dysfunction and Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2018, 8(6): 9-20.
[3]	ZHANG Xiang-yang.Neurocognitive Impairment in Schizophrenia: Clinical Correlates and Pathophysiological Mechanisms[J]. Acta Neuropharmacologica, 2018, 8(5): 89-90.
[4]	CUI Su-ying, SONG Jin-zhi, CUI Xiang-yu, HU Xiao, DING Hui, YE Hui, ZHANG Yong-he.Intracerebroventricular Streptozocin-induced Alzheimer’s Disease-like Sleep Disorders: Role of the GABAergic System in the Parabrachial Complex[J]. Acta Neuropharmacologica, 2018, 8(5): 96-97.
[5]	YU Li-li1，2，XU Li1，WANG Yi-nuo1，XUE Lu-ning1，Gou Ji-wei1，LI Hong-bo1，HOU Xue-qin1，ZHANG Han-ting1.Effects of Osthole on Learning and Memory and the Estrogen Pathway in Ovariectomized Rats[J]. Acta Neuropharmacologica, 2018, 8(4): 7-8.
[6]	WANG Hao1, ZHANG Fang-fang1, FU Hua-rong1, ZHOU Yan-meng1, LIU Xin1, HOU Xue-qin 1, HU Wei2, Rolf Hansen2, XU Ying3, James O’Donnell3, ZHANG Han-ting1,2.Targeting PDE4 for Alzheimer’s Disease and Alcoholism: An implication in Alcohol-Related Dementia?[J]. Acta Neuropharmacologica, 2018, 8(4): 39-41.
[7]	YANG Wen-zhong1, ZHOU Xue-yan1, MA Tao1,2,3*.Impaired mRNA Translational Capacity is Correlated with Aging-Dependent Memory Deficits and Behavioral Inflexibility[J]. Acta Neuropharmacologica, 2018, 8(4): 50-52.
[8]	WANG Jia-Yue，DUAN Yan-Hong，Wang Xin-He，Zhang Xu-Liang，Xu Mei-Chen, Cao Xiao-Hua *.The Effect of PHA-543613 on Memory Disorders in Presenilin1 and Presenilin2 Conditional Double Knockout Mice[J]. Acta Neuropharmacologica, 2018, 8(4): 52-53.
[9]	ZHU Min1, LI Ling-hai2.Advances in Research on Application of Anesthetics and Postoperative Cognitive Dysfunction in Patients[J]. Acta Neuropharmacologica, 2018, 8(3): 32-.
[10]	LIN Zhi-bin.Pharmacological Progress of Ganoderma on Anti-aging and Anti-Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2018, 8(1): 9-15.
[11]	LIU Nuo，WANG Zhen-zhen，CHEN Nai-hong.The Role of Gut Flora in the Pathogenesis of Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2017, 7(5): 28-.
[12]	GAO Zhi-hong1，ZUO Ya-qi2，ZHANG Xiao-li1.A New Idea of Astragaloside-Induced Bone Marrow Mesenchymal Stem Cells in the Treatment of Parkinson’s Disease[J]. Acta Neuropharmacologica, 2017, 7(5): 39-44.
[13]	REN Jing，ZHANG Dan-shen.Research Progress of Curcumin in the Treatment of Nervous System Diseases[J]. Acta Neuropharmacologica, 2017, 7(5): 45-51.
[14]	HOU Wen-shu，ZHANG Li.Research Progress on Therapeutic Target of Effective Ingredients of Traditional Chinese Medicine in Treating Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2017, 7(5): 59-64.
[15]	WAN Ye，GUO Chun-yan，LI Yong-min.Research Progress of Traditional Chinese Medicine in Parkinson’s Disease[J]. Acta Neuropharmacologica, 2017, 7(4): 36-42.